Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer
Public ClinicalTrials.gov record NCT05534646. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase II Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer
Study identification
- NCT ID
- NCT05534646
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 100 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 26, 2023
- Primary completion
- Dec 31, 2026
- Completion
- Dec 31, 2026
- Last update posted
- Feb 1, 2026
2023 – 2027
United States locations
- U.S. sites
- 3
- U.S. states
- 2
- U.S. cities
- 3
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope | Duarte | California | 91010 | Recruiting |
| Cedars-Sinai Medical Center | Los Angeles | California | 90048 | Recruiting |
| Huntsman Cancer Institute and Hospital | Salt Lake City | Utah | 84112 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Castration-resistant Prostate Cancer trials
Other public records listing Castration-resistant Prostate Cancer. Sorted by last update posted; newest first. Not a recommendation.
- NCT07745361: Study of Oral MRT-2359 With Apalutamide in Prostate Cancer Recruiting
- NCT04090528: pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer Active, not recruiting
- NCT06966024: Study of DCC-2812 in Participants With Advanced Genitourinary Cancers Recruiting
- NCT07545811: Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer Recruiting
- NCT06378866: Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial Recruiting
- NCT07503808: A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05534646, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 1, 2026 · Synced May 13, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05534646 live on ClinicalTrials.gov.